Suggested remit: To appraise the clinical and cost effectiveness of itulazax 12 standardised quality pollen from white birch (betula verrucosa) sublingual lyophilisate immunotherapy (12 SQ-Bet SLIT) within its marketing authorisation for treating moderate-to-severe allergic rhinitis, conjunctivitis, or both, induced by pollen from the birch homologous group in people 5 to 17 years old.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6537
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 August 2025 - 24 September 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6537 |
| 27 August 2025 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 08 October 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 08 October 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual